Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopregnanolone IM bridging study in early Alzheimer's disease
NCT03748303Phase 1Terminated
- Sponsor
- University of Arizona
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexanolone in Alzheimer's disease (AD), sponsored by University of Arizona. Primary endpoints: Adverse events at 14 weeks and Clinical laboratory measures at 14 weeks. Started Oct 2019; status: terminated.
02
Drugs
brexanolone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03748303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748303.